Schoenherr has advised the shareholders of Vienna-headquartered biotech company Eucodis Bioscience on the sale of the company to the Biosynth Group. Reportedly, Gibson Dunn & Crutcher and E+H advised the Biosynth Group.
Biosynth is a Swiss life sciences reagents, custom synthesis, and manufacturing services company specializing in complex chemistry, peptides, and key biological raw materials.
According to Schoenherr, “Eucodis is an expert in engineering and developing enzymes for pharma, biotech, and applied markets. The transaction involved the coordination of a total of 19 sellers and structuring and implementing the concurrent termination and payoff of equity participation instruments. It closed on October 17, 2022, after the transaction received the required FDI clearance.”
Schoenherr’s team included Partners Robert Bachner and Dominik Hofmarcher, Counsel Marco Thorbauer, Attorney at Law Daniel Wadl, and Associate Leonhard Telsnig.
